Imipramine Is Effective in Preventing Relapse in Electroconvulsive Therapy-Responsive Depressed Inpatients With Prior Pharmacotherapy Treatment Failure: A Randomized, Placebo-Controlled Trial
J Clin Psychiatry 2006;67:263-268
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To compare the efficacy of
imipramine versus placebo in preventing relapse after
successful electroconvulsive therapy (ECT) in
depressive inpatients with pharmacotherapy
treatment failure prior to ECT.
Method: During a 6-month period, the
incidence of relapse was assessed. Two centers, both
inpatient units for treatment of depressed patients,
participated in this trial. Patients with
DSM-IV-diagnosed major depressive disorder resistant to an
antidepressant and subsequent lithium addition and/or
a monoamine oxidase inhibitor were included. Patients were randomly assigned to
double-blind treatment with imipramine with adequate
plasma levels (N = 12) or placebo (N = 15) after
successful ECT. The mean imipramine dosage was 209
mg/day (standard deviation: 91.7, range: 75 - 325 mg/day). The main outcome measure was relapse
defined as at least "moderately worse" compared
with baseline score on the Clinical Global
Impressions-Improvement scale. Treatments were
compared with survival analysis using the Cox
proportional hazards model, including psychotic features and
the score on the Hamilton Rating Scale for
Depression (HAM-D) at baseline as prespecified
covariables. Patients were enrolled in the study from April
1997 to July 2001.
Results: In the placebo group, 80% (12/15)
of the patients relapsed compared with 18% (2/11)
in the imipramine group. The Cox regression
analysis showed a significant reduction in the risk of
relapse of 85.6% with imipramine compared to
placebo (p = .007; 95% confidence interval [CI] = 24.6%
to 97.2%) adjusted for the covariables. There was
an 18% increase in the relapse rate (p = .032; 95% CI = 2% to 36%) per unit increase in HAM-D
score before the start of the trial; psychotic features
had no significant effect (p = .794).
Conclusions: Depressed patients with
pharmacotherapy treatment failure may benefit from
the prophylactic effect of the same class of drug
during maintenance therapy after response to ECT.